Navigation Links
Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Date:5/5/2009

JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTC: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced that Phase 2b clinical trials will commence this week on 30 Type 2 Diabetic volunteers. The study is intended to evaluate the safety, tolerability and efficacy of its oral insulin capsule ORMD-0801. OnQ Consulting, a clinical research organization (CRO) located in Johannesburg, South Africa, will oversee the clinical trials. This trial is an important milestone for Oramed as it will test its first indication for ORMD-0801 on a large group of volunteers for the duration of six weeks.

This six week randomized, double blind placebo controlled study will be performed in three locations in Cape Town. The principle investigators of the study will be renowned South African Endocrinologists.

"We are pleased to begin this study of ORMD-0801 on Type 2 diabetes patients following our successful 2A clinical trials in August 2008. This trial is an important milestone for Oramed as this is the first trial for ORMD-0801 on a larger group of volunteers for a longer duration." said Oramed's CEO, Mr. Nadav Kidron.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    Cell:   +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
2. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
3. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
4. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
5. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
8. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
9. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
10. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
11. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... http://www.researchandmarkets.com/research/bcrl3s/labelfree ) ... "Label-Free Detection Market by Technology, Products, Applications ... to their offering. --> http://www.researchandmarkets.com/research/bcrl3s/labelfree ... "Label-Free Detection Market by Technology, Products, ... report to their offering. --> ...
(Date:2/8/2016)... 8, 2016  Astellas Pharma Inc. President and Chief Executive ... James Robinson as president, Americas Operations, for Astellas ... and South America , effective April 1, ... the commercial organization in the United States ... Masao Yoshida , who is retiring in June 2016.  ...
(Date:2/8/2016)... 2016  LivaNova, PLC, Hersteller des VNS-Therapie ... dem Titel „Epilepsy Around the World" (Epilepsie ... Krankheit gegenüber ein größeres Bewusstsein gefördert werden ... bei Epilepsie auf dem Internationalen Epilepsietag zu ... Mithilfe der neuen Infografik sollen wichtige Statistiken ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's document management software ... provides a cloud hosted environment for FileHold software that is pay per user ... party applications using the FileHold web services API. DocuSyst also advises clients on ...
(Date:2/8/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a product ... from a cluster of melanin when exposed to sunlight. Although most moles are benign ... of embarrassment. Historically, mole removal has involved a painful, often expensive visit ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... four states in the U.S. require dental technicians to be certified or obtain ... dental industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin Harrington, along ... new DRTV campaign with Belly Bands. , Having a dog is great—except when it ... pads and find nothing works, get Belly Bands, the easiest way to stop ...
Breaking Medicine News(10 mins):